Compare British American Tobacco PLC (BTI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Neurocrine Biosciences Inc — how do they compare? British American Tobacco PLC trades at $55.92 (market cap $122.36B), while Neurocrine Biosciences Inc trades at $157.22 (market cap $16.46B). The key difference: British American Tobacco PLC is far larger — about 7.4× Neurocrine Biosciences Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BTI | NBIX | |
|---|---|---|
Market Cap | $122.36B | $16.46B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $185.50 |
52-Week Low | $50.39 | $123.10 |
Enterprise Value | $166.31B | $16.48B |
Dividend Yield | 5.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $57.05, down 3.84% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 24.99% net income margin and 13.33% ROE. Recent earnings show three beats out of four quarters, while cash flow turned negative in 2025. The company is pivoting to next-generation nicotine products like Velo, supported by a multi-year tech partnership with ITC Infotech announced in August 2026.
The outlook is mixed: valuation appears reasonable with a P/E of 14.48, and analyst consensus is 66.7% buy ratings, but technical indicators are bearish and regulatory risks persist. The stock offers income potential with dividends, yet faces headwinds from declining combustibles and recent workforce cuts.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
